We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
Cap. Flow
-$21M
Cap. Flow %
-0.9%
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$95.5M
2
VERA icon
Vera Therapeutics
VERA
+$82M
3
CLDX icon
Celldex Therapeutics
CLDX
+$53.3M
4
ABVX
Abivax
ABVX
+$39.5M
5
BLTE
Belite Bio
BLTE
+$38.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$190M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$84.4M
3
TERN
Terns Pharmaceuticals
TERN
+$79.1M
4
CYTK icon
Cytokinetics
CYTK
+$57.7M
5
UTHR icon
United Therapeutics
UTHR
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDIT icon
51
Editas Medicine
EDIT
$485M
$7.2M 0.31%
+2,222,000
New +$6.49M
RLAY icon
52
Relay Therapeutics
RLAY
$4.11B
$6.55M 0.28%
350,000
-400,000
-53% -$5.81M
ACAD icon
53
Acadia Pharmaceuticals
ACAD
$5.02B
$6.33M 0.27%
250,000
-500,000
-67% -$11M
AMLX icon
54
Amylyx Pharmaceuticals
AMLX
$3.87B
$6.29M 0.27%
350,000
-350,000
-50% -$5.41M
HELP
55
Cybin Inc
HELP
$890M
$4.96M 0.21%
+750,000
New +$3.75M
OKUR
56
OnKure Therapeutics
OKUR
$153M
$4.4M 0.19%
+963,855
New +$4.14M
TENX icon
57
Tenax Therapeutics
TENX
$79.7M
$4.37M 0.19%
300,000
-325,000
-52% -$4.15M
DFTX
58
Definium Therapeutics
DFTX
$5.51B
$3.76M 0.16%
+80,000
New +$1.98M
UNCY icon
59
Unicycive Therapeutics
UNCY
$147M
$2.22M 0.1%
473,563
– –
PTN
60
Palatin Technologies
PTN
$18.6M
$1.4M 0.06%
130,000
-10,000
-7% -$165K
QURE icon
61
uniQure
QURE
$3.38B
$1.38M 0.06%
+30,000
New +$785K
JATT
62
JATT II Acquisition Corp
JATT
$93.6M
$1.14M 0.05%
+100,000
New +$1.06M
RACC
63
Research Alliance Corp III
RACC
$195M
$1.07M 0.05%
+100,000
New +$1.04M
ACRS icon
64
Aclaris Therapeutics
ACRS
$885M
$1.06M 0.05%
200,000
-300,000
-60% -$1.34M
LGVN
65
Longeveron
LGVN
$21.4M
$905K 0.04%
+128,700
New +$1.11M
GUTS icon
66
Fractyl Health
GUTS
$105M
$794K 0.03%
1,000,000
– –
SEPN
67
Septerna Inc
SEPN
$1.82B
$789K 0.03%
23,548
– –
AMAN
68
Amanat Acquisition Corp
AMAN
$104M
$508K 0.02%
+50,000
New +$505K
ALKS icon
69
Alkermes
ALKS
$7.95B
– –
-350,000
Closed -$12.4M
AVTX icon
70
CALL
Avalo Therapeutics
AVTX
$1.05B
– –
-1,000,000
Closed -$14.9M
BIIB icon
71
Biogen
BIIB
$32.3B
– –
-200,000
Closed -$36.7M
CMPX icon
72
Compass Therapeutics
CMPX
$432M
– –
-3,150,000
Closed -$16.7M
CNTA
73
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-2,125,000
Closed -$84.4M
CRVS icon
74
Corvus Pharmaceuticals
CRVS
$1.19B
– –
-450,000
Closed -$6.58M
CYTK icon
75
Cytokinetics
CYTK
$10B
– –
-875,000
Closed -$57.7M
1 2
3
4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2026 Portfolio in Review

As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.

  • Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
  • Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
  • Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
  • Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
  • Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
  • Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.